How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Pharma and Healthcare · Forecast 2027–2033
Peripheral Stent Graft Market
- By Product Type: Thoracic Stent Grafts, Abdominal Stent Grafts, Iliac Stent Grafts, Fenestrated Stent Grafts, Branched Stent Grafts
- By Material: Nitinol Stent Grafts, Stainless Steel Stent Grafts, Polyester Fabric Grafts, ePTFE (Expanded Polytetrafluoroethylene) Grafts
- By End User: Hospitals, Specialty Vascular Clinics, Ambulatory Surgical Centers
- By Indication: Peripheral Artery Disease (PAD), Abdominal Aortic Aneurysm (AAA), Thoracic Aortic Aneurysm (TAA), Traumatic Vascular Injuries
- By Procedure Type: Endovascular Aneurysm Repair (EVAR), Thoracic Endovascular Aortic Repair (TEVAR), Fenestrated Endovascular Repair
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Projected to reach $X,XXX.XM by 2033 on sustained demand. Market Outlook →
- 03 Growth - X.XX% CAGR across 2027–2033, with the full year-by-year model inside. Market Outlook →
- 04 Leading segment - Thoracic Stent Grafts leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Peripheral Stent Graft Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Material 4
End User 3
Indication 4
Procedure Type 3
Companies profiled
Medtronic
W.L. Gore & Associates
Terumo Corporation
Cook Medical (a subsidiary of Medtronic)
Becton Dickinson (BD)
Endologix (acquired by Terumo)
C.R. Bard (now part of BD)
Abbott Laboratories
Boston Scientific
Jotec GmbH
Cardinal Health
Vascular Innovations Co. Ltd.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →W.L. Gore & Associates
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Cook Medical (a subsidiary of Medtronic)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Becton Dickinson (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Endologix (acquired by Terumo)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →C.R. Bard (now part of BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Abbott Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Boston Scientific
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Jotec GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Cardinal Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Vascular Innovations Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →LeMaitre Vascular
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Bolton Medical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →InCraft
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$4,265M by 2033 · 9.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Thoracic Stent Grafts35.9
- Abdominal Stent Grafts15.1
- Iliac Stent Grafts20.2
- Fenestrated Stent Grafts11.3
- Branched Stent Grafts17.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$662.2M → $1,559M · 11.3%
Europe$461.6M → $919.5M · 9.0%
Asia Pacific$421.4M → $863.1M · 9.4%
Latin America$260.9M → $610.2M · 11.2%
Middle East and Africa$200.7M → $475.2M · 11.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.842026
9.852027
9.872028
9.862029
9.882030
9.892031
9.902032
9.912033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic8.7
- W.L. Gore & Associates22.2
- Terumo Corporation8.3
- Cook Medical (a subsidiary of Medtronic)12.3
- Becton Dickinson (BD)7.5
- Endologix (acquired by Terumo)13.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type12.8%
Material17.1%
End User31.3%
Indication25.6%
Procedure Type13.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.2
- Europe20.8
- Asia Pacific19.5
- Latin America13.8
- Middle East and Africa10.7
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic | 91 | 78 | 77 | 89 | 98 | 83 | 86 |
| W.L. Gore & Associates | 75 | 93 | 84 | 72 | 83 | 69 | 79 |
| Terumo Corporation | 66 | 86 | 73 | 65 | 87 | 74 | 75 |
| Cook Medical (a subsidiary of Medtronic) | 58 | 61 | 72 | 65 | 80 | 68 | 67 |
| Becton Dickinson (BD) | 62 | 72 | 60 | 71 | 62 | 54 | 64 |
| Endologix (acquired by Terumo) | 53 | 67 | 51 | 67 | 63 | 51 | 59 |
| C.R. Bard (now part of BD) | 65 | 52 | 62 | 64 | 62 | 52 | 60 |
| Abbott Laboratories | 40 | 53 | 41 | 51 | 42 | 58 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic
- W.L. Gore & Associates
- Terumo Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic | ✓ | ✓ | ◐ | ◐ | ✓ | ✓ |
| W.L. Gore & Associates | ◐ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Terumo Corporation | ◐ | ◐ | ◐ | − | ✓ | ◐ |
| Cook Medical (a subsidiary of Medtronic) | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Becton Dickinson (BD) | − | ✓ | ◐ | ◐ | ◐ | − |
| Endologix (acquired by Terumo) | ◐ | ◐ | ◐ | ◐ | − | − |
| C.R. Bard (now part of BD) | ◐ | ◐ | ◐ | ✓ | ◐ | − |
| Abbott Laboratories | − | ◐ | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medtronic86
2W.L. Gore & Associates79
3Terumo Corporation75
4Cook Medical (a subsidiary of Medtronic)67
5Becton Dickinson (BD)64
6C.R. Bard (now part of BD)60
7Endologix (acquired by Terumo)59
8Abbott Laboratories48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
MedtronicW.L. Gore & Associates
Challenger2
Strong scale, closing on the leaders.
Terumo CorporationCook Medical (a subsidiary of Medtronic)
Contender3
Focused players with pockets of strength.
Becton Dickinson (BD)Endologix (acquired by Terumo)C.R. Bard (now part of BD)
Niche1
Specialists in a single segment or region.
Abbott Laboratories
Go-to-market strategy
Land Product Type in North America, then scale across Peripheral Stent Graft Market — a $253M beachhead inside a $3.80B market.
Beachhead (SOM)$253Mobtainable near-term
Serviceable (SAM)$1.58Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Thoracic Stent Grafts
Best fit — highest urgency & budget in Product Type.
Economic buyer80 fit
Abdominal Stent Grafts
Strong fit — clear ROI and a fast path to value.
End user70 fit
Iliac Stent Grafts
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Material & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel29%
Digital / self-serve19%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Peripheral Stent Graft Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified25%
Evaluation13%
Closed-won6%
$13.2KCAC
$49KLTV
3.7:1LTV : CAC
< 4 moCAC payback
Investment thesis
Peripheral Stent Graft Market is a durable-growth opportunity — $2.56B by 2033, compounding at 6.8%.
TAM · 2025$1.51Btoday
TAM · 2033$2.56Bforecast
CAGR6.8%2027–2033
Cumulative$18.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.56BTotal addressable market
SAM$1.01BServiceable available market
SOM$214MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.8% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.56BLarge & growingTAM by 2033 at 6.8% CAGR
$1.01BServiceable nowreachable with today’s model
$214MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.00BBear4.4% CAGR
$2.56BBase6.8% CAGR
$3.28BBull9.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Material optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Peripheral Stent Graft Market — a $4.15B market by 2033. Plan: grow share from 9.1% to 14.4%.
Market size · 2033$4.15Btotal addressable
Market CAGR3.9%2027–2033
Target share14.4%from 9.1% today
Revenue ambition$597Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.1% | 14.4% | Ahead |
| Revenue | $347M | $597M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 30.6% | 39.2% | Ahead |
| Customer retention | 87.2% | 95.6% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Material capability
A defensible second engine — invest in Material to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Material
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $62M capacity & capability investment
- Greenlight bolt-on M&A in Material
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskAhead
- Regulatory / policy changeAhead
- Execution & talentOn track
Sales deck · value proposition
Win the Peripheral Stent Graft Market conversation — a $8.43B market you can size, segment and defend in minutes.
Market size · 2033$8.43Btotal opportunity
Growth9.6%CAGR to 2033
Addressable buyers1,570+accounts in scope
Typical ROI6.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.6×return on cost, year one
< 3 mopayback period
$90K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
MedtronicW.L. Gore & AssociatesTerumo CorporationCook Medical (a subsidiary of Medtronic)Becton Dickinson (BD)Endologix (acquired by Terumo)C.R. Bard (now part of BD)Abbott Laboratories+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Peripheral Stent Graft Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Peripheral Stent Graft Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Pharma and Healthcare · scroll →Positron Emission tomography (Pet) Scanners Market
Market size, share, segmentation and regional forecast.
$6.4B by 2031 · 10.40% CAGR
View reportSurgical Adhesion Barriers Market
Market size, share, segmentation and regional forecast.
$9.1B by 2031 · 9.73% CAGR
View reportSurgical hook Market
Market size, share, segmentation and regional forecast.
$8.8B by 2031 · 7.94% CAGR
View reportProphylactic Human Vaccine Market
Market size, share, segmentation and regional forecast.
$3.6B by 2031 · 8.08% CAGR
View reportOropharyngeal Airways Market
Market size, share, segmentation and regional forecast.
$4.5B by 2031 · 10.53% CAGR
View reportTherapeutic Stent Market
Market size, share, segmentation and regional forecast.
$3.2B by 2031 · 4.07% CAGR
View reportMedical Suction Devices Market
Market size, share, segmentation and regional forecast.
$2.9B by 2032 · 10.56% CAGR
View reportPolio Vaccines Market
Market size, share, segmentation and regional forecast.
$3.1B by 2032 · 6.38% CAGR
View reportPreventive Vaccine Market
Market size, share, segmentation and regional forecast.
$11.5B by 2031 · 5.05% CAGR
View reportOperating Room Equipments Market
Market size, share, segmentation and regional forecast.
$9.0B by 2032 · 4.87% CAGR
View reportOxygen Conserver Device Market
Market size, share, segmentation and regional forecast.
$11.4B by 2031 · 5.20% CAGR
View reportOxygen Therapy Equipments Market
Market size, share, segmentation and regional forecast.
$13.9B by 2033 · 3.83% CAGR
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.